11 December 2019

Kuros Biosciences (SIX: KURN) completes a rights offering and share placement in which a total of 6,405,022 new registered shares of Kuros sourced from the ordinary and authorized share capital with a nominal value of CHF 1.00 each were offered at an offer price of CHF 1.95 per share. Total gross proceeds raised from the capital increase amount to CHF 12.5 million. Kuros intends to use the proceeds of the offering in its discretion for the commercialization of its products and the further development of its product candidates.

VISCHER AG advised Kuros Biosciences with Matthias Staehelin (Partner, Corporate), Angelo Imperiale (Senior Associate, Corporate) and Nadia Tarolli (Partner, Tax).

Categories: Banking & Finance, Corporate and Commercial, Life Sciences, Pharma, Biotech

You are currently offline. Some pages or content may fail to load.